Black Diamond Therapeutics, Inc. (BDTX) Investor Relations Documents

Black Diamond Therapeutics, Inc. (BDTX) investor relations documents from the company's IR site: 1 presentation, 8 press releases; latest deck 2026-05-29. Read in-app with summaries. First-party data.

Safety and Efficacy Results of the Phase 2 Study of Silevertinib (BDTX-1535) in Treatment-Naïve Patients with Non-Small : Phase 2 study of silevertinib (BDTX-1535) in treatment-naïve NSCLC with non-classical EGFR mutations shows a 60% objective response rate and 15.2-month median PFS.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseBlack Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-05-29PresentationSafety and Efficacy Results of the Phase 2 Study of Silevertinib (BDTX-1535) in Treatment-Naïve Patients with Non-Small
2026-05-22Press releaseBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
2026-05-21Press releaseBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non
2026-05-19Press releaseBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib
2026-05-07Press releaseBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-21Press releaseBlack Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at
2026-03-16Press releaseBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-02Press releaseBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX overview · BDTX earnings · BDTX financials · BDTX KPIs · BDTX ownership · BDTX peers · BDTX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.